Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × NSCLC × sintilimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 25 Carcinoma, Hepatocellular 23 Carcinoma, Non-Small-Cell Lung 18 Colorectal Neoplasms 13 Esophageal Squamous Cell Carcinoma 9 Lung Neoplasms 8 Nasopharyngeal Carcinoma 7 Cholangiocarcinoma 6 Squamous Cell Carcinoma of Head and Neck 5 Rectal Neoplasms 5 Pancreatic Neoplasms 4 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 3 Neoplasms 3 Lymphoma, Extranodal NK-T-Cell 3 Esophageal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Sarcoma 2 Nonsquamous Non-Small Cell Lung Cancer 2 Neuroendocrine Tumors 2 Lymphoma, Large B-Cell, Diffuse 2 Locally Advanced Rectal Cancer 2 Glioblastoma 2 Gastric Adenocarcinoma 2 Colorectal Cancer Metastatic 2 Carcinoma, Neuroendocrine 2 Carcinoma 2

Interventions

osimertinib 5 Carboplatin 5 Drug Therapy 4 tislelizumab 3 anlotinib 3 aflutinib 3 Radiotherapy 3 Pemetrexed 3 toripalimab 2 pembrolizumab 2 apatinib 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Radiosurgery 2 Paclitaxel 2 HM781-36B 2 Cisplatin 2 Chemotherapy, Adjuvant 2 Chemoradiotherapy 2 trilaciclib 1 surufatinib 1 sintilimab 1 rezivertinib 1 lenvatinib 1 icotinib 1 envafolimab 1 dacomitinib 1 cemiplimab 1 camrelizumab 1 brigatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06479759 2024-06-28

ACCLAIM

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2 Recruiting

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡